Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review

被引:8
|
作者
Rao, Prakruti S. [1 ]
Modi, Nisha [2 ,3 ]
Nguyen, Nam-Tien Tran [4 ]
Vu, Dinh Hoa [4 ]
Xie, Yingda L. [2 ,3 ]
Gandhi, Monica [5 ]
Gerona, Roy [6 ]
Metcalfe, John [7 ,8 ]
Heysell, Scott K. [1 ]
Alffenaar, Jan-Willem C. [9 ,10 ,11 ]
机构
[1] Univ Virginia, Div Infect Dis & Int Hlth, Charlottesville, VA USA
[2] Rutgers State Univ, Global TB Inst, Newark, NJ USA
[3] Rutgers State Univ, Dept Med, Newark, NJ USA
[4] Hanoi Univ Pharm, Natl Drug Informat & Adverse Drug React Monitorin, Hanoi, Vietnam
[5] Univ Calif San Francisco, Dept Med, Div HIV Infect Dis & Global Med, San Francisco, CA USA
[6] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, Maternal Fetal Med Div, San Francisco, CA USA
[7] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Div Pulm & Crit Care Med, San Francisco, CA USA
[8] Univ Calif San Francisco, Trauma Ctr, San Francisco, CA USA
[9] Univ Sydney, Pharm Sch, Pharm Bldg A15,Sci Rd, Sydney, NSW 2006, Australia
[10] Univ Sydney, Westmead Hosp, Sydney, NSW, Australia
[11] Univ Sydney, Sydney Inst Infect Dis, Sydney, NSW, Australia
基金
美国国家卫生研究院;
关键词
DRIED BLOOD SPOTS; RESISTANT TUBERCULOSIS; ARKANSAS METHOD; LEVOFLOXACIN PHARMACOKINETICS; ANTITUBERCULOSIS DRUGS; PULMONARY TUBERCULOSIS; ISONIAZID TREATMENT; URINE COLORIMETRY; COLOR TEST; LC-MS/MS;
D O I
10.1007/s40262-023-01220-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and ObjectiveQuantifying exposure to drugs for personalized dose adjustment is of critical importance in patients with tuberculosis who may be at risk of treatment failure or toxicity due to individual variability in pharmacokinetics. Traditionally, serum or plasma samples have been used for drug monitoring, which only poses collection and logistical challenges in high-tuberculosis burden/low-resourced areas. Less invasive and lower cost tests using alternative biomatrices other than serum or plasma may improve the feasibility of therapeutic drug monitoring.MethodsA systematic review was conducted to include studies reporting anti-tuberculosis drug concentration measurements in dried blood spots, urine, saliva, and hair. Reports were screened to include study design, population, analytical methods, relevant pharmacokinetic parameters, and risk of bias.ResultsA total of 75 reports encompassing all four biomatrices were included. Dried blood spots reduced the sample volume requirement and cut shipping costs whereas simpler laboratory methods to test the presence of drug in urine can allow point-of-care testing in high-burden settings. Minimal pre-processing requirements with saliva samples may further increase acceptability for laboratory staff. Multi-analyte panels have been tested in hair with the capacity to test a wide range of drugs and some of their metabolites.ConclusionsReported data were mostly from small-scale studies and alternative biomatrices need to be qualified in large and diverse populations for the demonstration of feasibility in operational settings. High-quality interventional studies will improve the uptake of alternative biomatrices in guidelines and accelerate implementation in programmatic tuberculosis treatment.
引用
收藏
页码:375 / 398
页数:24
相关论文
共 50 条
  • [31] Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis
    Maranchick, Nicole F.
    Peloquin, Charles A.
    JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES, 2024, 36
  • [32] Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
    Falzon, Dennis
    Jaramillo, Ernesto
    Gilpin, Christopher
    Weyer, Karin
    EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (04)
  • [33] Therapeutic Drug Monitoring of ImatinibBayesian and Alternative Methods to Predict Trough Levels
    Verena Gotta
    Nicolas Widmer
    Michael Montemurro
    Serge Leyvraz
    Amina Haouala
    Laurent A. Decosterd
    Chantal Csajka
    Thierry Buclin
    Clinical Pharmacokinetics, 2012, 51 : 187 - 201
  • [34] Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?
    Pasipanodya, Jotam G.
    Gumbo, Tawanda
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (05) : 717 - 718
  • [35] Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?
    Zuur, Marlanka A.
    Akkerman, Onno W.
    Forsman, Lina Davies
    Hu, Yi
    Zheng, Rongdong
    Bruchfeld, Judith
    Tiberi, Simon
    Migliori, Giovanni Battista
    Alffenaar, Jan-Willem C.
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48 (04) : 1230 - 1233
  • [36] Amperometric biosensors for clinical and therapeutic drug monitoring: a review
    Wang, J
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1999, 19 (1-2) : 47 - 53
  • [37] Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact
    Galar, Alicia
    Valerio, Maricela
    Munoz, Patricia
    Alcala, Luis
    Garcia-Gonzalez, Xandra
    Burillo, Almudena
    Sanjurjo, Maria
    Grau, Santiago
    Bouza, Emilio
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (10)
  • [38] Cost-effectiveness of therapeutic drug monitoring - A systematic review
    Touw, DJ
    Neef, C
    Thomson, AH
    Vinks, AA
    THERAPEUTIC DRUG MONITORING, 2005, 27 (01) : 10 - 17
  • [39] Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review
    Van Herwaarden, Noortje
    Van den Bemt, Bart J. F.
    Wientjes, Maike H. M.
    Kramers, Cornelis
    Den Broeder, Alfons A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (08) : 843 - 857
  • [40] PBPK Modeling and Simulation and Therapeutic Drug Monitoring: Possible Ways for Antibiotic Dose Adjustment
    Ferreira, Abigail
    Lapa, Rui
    Vale, Nuno
    PROCESSES, 2021, 9 (11)